glycyl-arginyl-glycyl-aspartyl-serine has been researched along with Urinary Bladder Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, CS; Hyacinthe, LM; Jarrett, TW; Vaughan, ED; Whalen, GF | 1 |
| Ardelt, P; Böhle, A; Brandau, S; Jocham, D; Jurczok, A; Ulmer, AJ; Wulf, T | 1 |
2 other study(ies) available for glycyl-arginyl-glycyl-aspartyl-serine and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS).
Topics: Animals; Antineoplastic Agents; Cautery; Cell Adhesion; Epithelium; Extracellular Matrix; Female; Heparin; Mannose; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oligopeptides; Urinary Bladder; Urinary Bladder Neoplasms; Wound Healing | 1995 |
Inhibition of bladder carcinoma cell adhesion by oligopeptide combinations in vitro and in vivo.
Topics: Animals; Cell Adhesion; Cell Line; Collagen Type I; Female; Fibronectins; Humans; Laminin; Mice; Mice, Inbred C57BL; Oligopeptides; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2002 |